Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Kyowa Kirin Chief Sees Late-Stage Assets as Next Japan Biz Drivers, Room for Growth for Duvroq/Crysvita
To read the full story
Related Article
- Kyowa Kirin’s FY2023 Sales Up by 2-Digits, Operating Profit Hits Record High
February 8, 2024
- Kyowa Kirin’s 6-Month Sales Up 7.5% as Global Brands Log Positive Growth
August 4, 2023
- Kyowa Kirin’s Crysvita Crosses Blockbuster Line: 2022 Earnings
February 8, 2023
- Kyowa Kirin Books 12.3% Growth in H1 on Global Portfolios, 9.8 Billion Yen FX Gain
August 5, 2022
BUSINESS
- Mitsubishi Tanabe’s Earnings Sink 2-Digits in FY2023 on Backlash from Previous Gilenya Royalties
May 17, 2024
- Eisai to Appoint CEO’s Son for Representative Post in Prelude to Succession
May 17, 2024
- Ultragenyx’s Evkeeza Gets Label Update to Allow Use under Age 5
May 17, 2024
- No Clenafin Generic Competition until June 2025: Kaken
May 17, 2024
- Japan Generic Market Set to Surpass 1.6 Trillion Yen by 2032: Fuji Keizai
May 17, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…